-
Featured Authors
-
Archives
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Author Archive: Tracy Cooley
Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.
Latest Posts
CFO Magazine: On the IPO On-Ramp
CFO Magazine highlighted the impact of the Jumpstart Our Business Startups (JOBS) Act on smaller companies aiming to obtain access to capital and the benefits of the JOBS Act by highlighting case studies from companies that went public using it. “Nearly everyone agrees that the JOBS Act has significantly affected the way IPOs are done,” writes Edward Teach. Teach talked to five companies to discuss their experiences, and not surprisingly, ‘all had strong opinions about Read More >
CNN: Sandy’s Story
CNN launched a new series profiling Sandy Halperin, a dentist and Harvard assistant professor, to raise awareness for the devastating impact of Alzheimer’s disease on a patient and his family. Producer Stephanie Smith describes Sandy’s Story as ‘an unprecedented look at the cruel journey of a vibrant, once healthy man as he gradually loses his memory.’ Halperin was diagnosed with early stage Alzheimer’s disease at age 60. The in-depth package explores the day-to-day reality of Read More >
Ebola Outbreak Highlights Value of Cures
Forbes recently published an op-ed comparing the outbreak and spread of the Ebola virus with the value of cures to prevent disease and save lives. The author – Merrill Matthews – is a resident scholar with the Institute for Policy Innovation in Dallas, Texas. Matthews asserts that drug companies are in the business of discovering cures for deadly and debilitating diseases, and need support for expediting research and development by cutting through red tape and Read More >
Jack the Ripper Mystery May Be Solved through DNA Testing
Author Russell Edwards and Jari Louhelainen, a molecular biology professor at Liverpool John Moores University claim to have solved the 126-year-old mystery surrounding the identity of Jack the Ripper, which is the pseudonym of a serial killer who murdered at least five women in East London in the late 1800s. Edwards bought a shawl that was found near the body of one of the victims – Catherine Eddowes – at an auction. He then worked Read More >
Patients Suffering from Gaucher’s Disease Deserve Better
Gaucher Disease is one of the over 6,000 rare diseases that affect patients worldwide, representing a frontier of unmet medical need [NCATS, NIH]. The challenges for drug development generally—long and costly research and development timelines—are exacerbated by the inherently small patient populations affected by rare diseases. These patients can be difficult to identify and geographically dispersed and their clinical presentation can be quite disparate, complicating the design and recruitment for clinical trials used to determine Read More >
